CClinicalTrials.gg
RecruitingNCT07332312Updated May 11, 2026

A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Indian and Alaska Native Cancer Patients Living in Rural California

An interventional study of Discussion and Discussion in Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by University of Southern California. Recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University of Southern California · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Apr 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Sex
All
01

Study summary

This clinical trial develops and tests whether a culturally informed patient navigation program, Community-Focused Patient Navigation (CFPN), works to reduce delays between diagnosis and treatment in American Indian and Alaska Native (AIAN) cancer patients living in rural California. AIAN communities face some of the most severe cancer disparities in the United States, including higher death rates, later-stage diagnoses, and limited access to timely, culturally responsive care. This may be due to barriers such as rural isolation, divided referral systems, or a lack of trust in mainstream healthcare systems. Patient navigation is a care delivery model designed to guide a patient through the healthcare system and address the barriers that prevent patients from accessing timely and effective care. The CFPN program is culturally tailored and designed with AIAN communities in mind. The program provides the patient with a treatment plan based on the patient's unique needs, goals, and barriers. This may be an effective way to reduce delays between diagnosis and treatment in AIAN cancer patients living in rural California.

Read the detailed description

PRIMARY OBJECTIVES:

I. Conduct a comprehensive community-informed planning process to co-design the Community-Focused Patient Navigation (CFPN) program.

II. Develop and implement an evidence and practice-informed, culturally responsive, CFPN program.

III. Evaluate the implementation and impact of the CFPN program using Practical, Robust Implementation and Sustainability Model (PRISM) and the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) frameworks, along with Indigenous evaluation practices.

OUTLINE: Participants are assigned to 1 of 2 objectives.

OBJECTIVE 1: Participants are assigned to 1 of 3 groups.

GROUP I: Participants serve on a Community Advisory Board (CAB) to guide the co-design process of the CFPN program on study.

GROUP II: Participants complete a focus group over 1-2 hours in support of the co-design process of the CFPN program on study.

GROUP III: Participants complete a key informant interview (KII) over 30 minutes in support of the co-design process of the CFPN program on study.

OBJECTIVE 2:

Patients engage with the CFPN program navigator as needed and receive a treatment plan based on the patient's needs, goals, and barriers on study. Patients also receive opioid misuse education and care coordination on study.

02

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
03

In context

Lead sponsor

University of Southern California is the lead sponsor of 773 studies on the registry; 135 are open to participants now.

Of its 68 completed or terminated interventional studies of FDA-regulated products, 32 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • CAB: Self-identify as AIAN or have experience working with the AIAN community
  • CAB: Are 18 years or older
  • CAB: Live within Toiyabe Indian Health Program (TIHP) catchment area(s)
  • CAB: Are either a cancer patient/survivor/caregiver and/or a family member of an individual(s) affected by cancer, OR a Board member (ex: Tribal Health Board or Elders Board)
  • FOCUS GROUP: Self-identify as AIAN or a family member of an AIAN individual affected by cancer
  • FOCUS GROUP: Are 18 years or older
  • FOCUS GROUP: Live within TIHP catchment area(s)
  • FOCUS GROUP: Are either a cancer patient/survivor/caregiver and/or a family member of an individual(s) affected by cancer, OR a Board member (ex: Tribal Health Board or Elders Board)
  • KII: Be a TIHP healthcare staff member
  • KII: Be 18 years or older
  • KII: Work with AIAN cancer patients in TIHP catchment area
  • CFPN PROGRAM IMPLEMENTATION: Have any type of cancer, are in any treatment stage along the cancer continuum
  • CFPN PROGRAM IMPLEMENTATION: Self-identify as AIAN or be a TIHP patient
  • CFPN PROGRAM IMPLEMENTATION: Live in the TIHP service area
  • CFPN PROGRAM IMPLEMENTATION: Receive cancer-related services from TIHP

Exclusion criteria

Exclusion Criteria:

  • FOCUS GROUP: Individual with no experience with cancer either as a patient or know someone who is/was a cancer patient at TIHP
  • CFPN PROGRAM IMPLEMENTATION: Not a TIHP patient
  • CFPN PROGRAM IMPLEMENTATION: Does not currently have cancer or has not previously had cancer
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Other
    Objective 1 group I (CAB)

    Participants serve on a CAB to guide the co-design process of the CFPN program on study.

    Other: Discussion

  • Other
    Objective 1 group II (focus group)

    Participants complete a focus group over 1-2 hours in support of the co-design process of the CFPN program on study.

    Other: Discussion

  • Other
    Objective 1 group III (KII)

    Participants complete a KII over 30 minutes in support of the co-design process of the CFPN program on study.

    Other: Interview

  • Experimental
    Objective 2 (CFPN program)

    Patients engage with the CFPN program navigator as needed and receive a treatment plan based on the patient's needs, goals, and barriers on study. Patients also receive opioid misuse education and care coordination on study.

    Other: Educational Intervention · Other: Electronic Health Record Review · Other: Interview · Behavioral: Patient Navigation · Other: Survey Administration · Procedure: Tailored Intervention

Interventions

  • OtherDiscussion

    Serve on CAB

    Also known as: Discuss

  • OtherDiscussion

    Complete focus group

    Also known as: Discuss

  • OtherEducational Intervention

    Receive opioid misuse education and care coordination

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherInterview

    Complete KII

  • OtherInterview

    Ancillary studies

  • BehavioralPatient Navigation

    Engage with CFPN program navigator

    Also known as: Patient Navigator Program

  • OtherSurvey Administration

    Ancillary studies

  • ProcedureTailored Intervention

    Receive treatment plan

06

What researchers measure

Primary outcomes

  1. Focus group themes and emerging codes

    Will compare themes and emerging codes utilizing qualitative coding computer software. A report will summarize participant responses for each focus group and will be discussed with the Toiyabe Indian Health Program (THIP) co-principal investigator (Co-PI) and staff prior to sharing with the Community Advisory Board (CAB) members.

    Time frame: Through study completion, up to 2 years

  2. Key informant interview findings and proposed strategies

    Will prepare a report with the findings and proposed strategies and discuss it with TIHP Co-PI and CAB.

    Time frame: Through study completion, up to 2 years

  3. Qualitative Effectiveness of Community-Focused Patient Navigation (CFPN) program

    Data collected in interviews focusing on patient's cancer journey and experience with the CFPN program will be analyzed using Dedoose software and an inductive qualitative approach. Two-coder teams will code separately and discuss discrepancies and reconciliations, and the codes will be applied to transcripts and fieldnotes.

    Time frame: Through study completion, up to 2 years

  4. Quantitative Effectiveness of Community-Focused Patient Navigation (CFPN) program

    Using Patient Satisfaction With Cancer Care Scale (Jean-Pierre, 2010) to collect data regarding the effectiveness of the CFPN program. Data will be analyzed using SAS to measure the unilateral satisfaction construct through descriptive statistics (e.g., means, medians, frequencies) and summarizing single-group satisfaction at post-intervention.

    Time frame: Through study completion, up to 2 years

  5. Implementation of Community-Focused Patient Navigation (CFPN) program

    Data will be collected via a study-specific patient survey to examine acceptability, appropriateness, and feasibility of the CFPN program. Data will be analyzed using SAS to calculate means, standard deviations, and ranges.

    Time frame: Through study completion, up to 2 years

  6. Attrition

    Number of patients lost to follow up will be examined to establish the reach of the Community-Focused Patient Navigation (CFPN) program.

    Time frame: Through study completion, up to 2 years

07

Study locations

2 of 2 sites recruiting
  • Toiyabe Indian Health Project
    Bishop, California 93514, United States
    Recruiting
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    • Claradina Soto · Contact · toya@usc.edu · 323-442-8219
    • Claradina Soto · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07332312
Lead sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI), American Cancer Society, Inc., Pfizer
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Apr 17, 2026
Primary completion
Nov 13, 2027 (estimated)
Completion
Nov 13, 2028 (estimated)
Last update
May 11, 2026

Study contacts

Claradina Soto
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion